TRIAL RESULTS · SIDE EFFECTS
Glucagon side effects
ANSWER
2 placebo-controlled trials of Glucagon posted side-effect results, but no side effect was reported for at least half of the 110 people on Glucagon, so no pooled comparison is shown. Read from ClinicalTrials.gov on 2026-10-03. Not medical advice.
Trial register
Trials with posted results
16
with an arm on Glucagon, of 1514 registered
Against placebo
2
placebo-controlled trials
People in those trials
110
on Glucagon · 83 on placebo
Read
2026-10-03
ClinicalTrials.gov
ALL TRIALS
The 100 most reported of 178 side effects reported
Every trial with posted results and an arm on Glucagon (n ≥ 20), all phases, by people affected. Placebo is shown where placebo-controlled trials reported the same event. Comparator arms are not counted.
| Side effect | Organ system | Glucagon | Placebo | Trials |
|---|---|---|---|---|
| Nausea | Gastrointestinal disorders | 25.9% (280 of 1,080) | 2.1% | 12 |
| Headache | Nervous system disorders | 19.0% (196 of 1,034) | - | 11 |
| Lacrimation increased | Eye disorders | 28.8% (163 of 565) | - | 5 |
| Vomiting | Gastrointestinal disorders | 11.0% (116 of 1,052) | 0.0% | 11 |
| Nasal Irritation | Respiratory, thoracic and mediastinal disorders | 77.0% (67 of 87) | - | 1 |
| Nasal discomfort | Respiratory, thoracic and mediastinal disorders | 11.4% (64 of 563) | - | 5 |
| Rhinorrhoea | Respiratory, thoracic and mediastinal disorders | 9.2% (41 of 446) | - | 5 |
| Nasal congestion | Respiratory, thoracic and mediastinal disorders | 6.7% (38 of 565) | - | 5 |
| Ocular hyperaemia | Eye disorders | 19.0% (35 of 184) | - | 2 |
| Dizziness | Nervous system disorders | 8.2% (23 of 280) | 2.1% | 5 |
| Eye pruritus | Eye disorders | 4.6% (22 of 478) | - | 4 |
| Sneezing | Respiratory, thoracic and mediastinal disorders | 7.5% (22 of 293) | - | 4 |
| Fatigue | General disorders | 5.8% (21 of 359) | - | 4 |
| Injection site pain | General disorders | 17.4% (21 of 121) | 38.3% | 2 |
| Somnolence | Nervous system disorders | 4.5% (20 of 446) | - | 5 |
| Nasal Discomfort | Respiratory, thoracic and mediastinal disorders | 86.4% (19 of 22) | - | 1 |
| Cough | Respiratory, thoracic and mediastinal disorders | 3.2% (18 of 563) | - | 5 |
| Dysgeusia | Nervous system disorders | 9.8% (18 of 184) | - | 2 |
| Nasal pruritus | Respiratory, thoracic and mediastinal disorders | 8.3% (18 of 216) | - | 2 |
| Watery Eyes | Eye disorders | 81.8% (18 of 22) | - | 1 |
| Parosmia | Nervous system disorders | 9.2% (17 of 184) | - | 2 |
| Rhinalgia | Respiratory, thoracic and mediastinal disorders | 4.6% (15 of 325) | - | 3 |
| Eye irritation | Eye disorders | 8.2% (15 of 184) | - | 2 |
| Blood glucose decreased | Investigations | 8.2% (15 of 184) | - | 2 |
| Hot flush | Vascular disorders | 2.7% (13 of 478) | - | 4 |
| Ear pain | Ear and labyrinth disorders | 2.4% (11 of 456) | - | 4 |
| Tremor | Nervous system disorders | 5.3% (11 of 206) | - | 3 |
| Throat irritation | Respiratory, thoracic and mediastinal disorders | 6.0% (11 of 184) | - | 2 |
| Injection Site Reaction | Skin and subcutaneous tissue disorders | 39.3% (11 of 28) | - | 1 |
| Hyperhidrosis | Skin and subcutaneous tissue disorders | 2.0% (10 of 498) | - | 5 |
| Eye pain | Eye disorders | 1.4% (9 of 629) | - | 5 |
| Asthenia | General disorders | 3.3% (9 of 271) | - | 3 |
| Feeling hot | General disorders | 4.3% (8 of 184) | - | 2 |
| Sinus headache | Nervous system disorders | 2.2% (6 of 271) | - | 3 |
| Diarrhoea | Gastrointestinal disorders | 1.5% (6 of 389) | - | 3 |
| Injection site discomfort | General disorders | 5.0% (6 of 121) | 2.1% | 2 |
| Head discomfort | Nervous system disorders | 3.7% (6 of 162) | - | 2 |
| Paraesthesia | Nervous system disorders | 3.3% (6 of 184) | - | 2 |
| Nasopharyngitis | Infections and infestations | 3.2% (6 of 185) | 4.3% | 2 |
| Nasal dryness | Respiratory, thoracic and mediastinal disorders | 2.7% (5 of 184) | - | 2 |
| Epistaxis | Respiratory, thoracic and mediastinal disorders | 2.0% (5 of 248) | - | 2 |
| Back pain | Musculoskeletal and connective tissue disorders | 1.2% (4 of 325) | - | 3 |
| Toothache | Gastrointestinal disorders | 1.4% (4 of 296) | 0.0% | 3 |
| Ocular discomfort | Eye disorders | 1.9% (4 of 214) | - | 2 |
| Pruritus | Skin and subcutaneous tissue disorders | 1.8% (4 of 228) | - | 2 |
| Paranasal sinus discomfort | Respiratory, thoracic and mediastinal disorders | 2.5% (4 of 162) | - | 2 |
| Hypoaesthesia | Nervous system disorders | 2.2% (4 of 184) | - | 2 |
| Hypoglycemia | Metabolism and nutrition disorders | 5.3% (4 of 75) | - | 1 |
| Blood pressure increased | Investigations | 2.8% (4 of 141) | - | 1 |
| Upper respiratory tract infection | Infections and infestations | 1.3% (3 of 230) | 4.3% | 3 |
| Abdominal discomfort | Gastrointestinal disorders | 0.9% (3 of 338) | 0.0% | 3 |
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | 0.9% (3 of 326) | 0.0% | 3 |
| Injection site reaction | General disorders | 2.5% (3 of 121) | 6.4% | 2 |
| Feeling cold | General disorders | 1.6% (3 of 184) | - | 2 |
| Pallor | Vascular disorders | 1.6% (3 of 184) | - | 2 |
| Dry throat | Respiratory, thoracic and mediastinal disorders | 1.6% (3 of 184) | - | 2 |
| Facial pain | General disorders | 1.3% (3 of 240) | - | 2 |
| Erythema | Skin and subcutaneous tissue disorders | 1.5% (3 of 196) | - | 2 |
| Injection site anaesthesia | General disorders | 4.0% (3 of 75) | - | 1 |
| Hot Flushes | Endocrine disorders | 10.7% (3 of 28) | - | 1 |
| Product taste abnormal | General disorders | 3.4% (3 of 87) | - | 1 |
| Abnormal sensation in eye | Eye disorders | 2.8% (3 of 109) | - | 1 |
| Blood pressure decreased | Investigations | 2.1% (3 of 141) | - | 1 |
| Hypertension | Vascular disorders | 0.9% (2 of 216) | - | 2 |
| Increased upper airway secretion | Respiratory, thoracic and mediastinal disorders | 1.1% (2 of 184) | - | 2 |
| Feeling abnormal | General disorders | 0.9% (2 of 228) | - | 2 |
| Cold sweat | Skin and subcutaneous tissue disorders | 0.8% (2 of 250) | - | 2 |
| Musculoskeletal discomfort | Musculoskeletal and connective tissue disorders | 2.7% (2 of 75) | - | 1 |
| Ear pruritus | Ear and labyrinth disorders | 2.7% (2 of 75) | - | 1 |
| Eye Pain | Eye disorders | 2.7% (2 of 75) | - | 1 |
| Injection site hypoaesthesia | General disorders | 2.7% (2 of 75) | - | 1 |
| Rhinitis | Infections and infestations | 2.7% (2 of 75) | - | 1 |
| Neck Pain | Musculoskeletal and connective tissue disorders | 2.7% (2 of 75) | - | 1 |
| Flushing | Endocrine disorders | 7.1% (2 of 28) | - | 1 |
| Gastrointestinal Pain | Gastrointestinal disorders | 7.1% (2 of 28) | - | 1 |
| Muscular weakness | Musculoskeletal and connective tissue disorders | 1.3% (2 of 153) | - | 1 |
| Abdominal Pain Upper | Gastrointestinal disorders | 9.1% (2 of 22) | - | 1 |
| Oral herpes | Infections and infestations | 1.8% (2 of 109) | - | 1 |
| Procedural dizziness | Injury, poisoning and procedural complications | 1.8% (2 of 109) | - | 1 |
| Blood potassium increased | Investigations | 1.8% (2 of 109) | - | 1 |
| Flatulence | Gastrointestinal disorders | 0.8% (1 of 121) | 0.0% | 2 |
| Urinary tract infection | Infections and infestations | 0.8% (1 of 121) | 2.1% | 2 |
| Neck pain | Musculoskeletal and connective tissue disorders | 0.5% (1 of 199) | 0.0% | 2 |
| Iron deficiency anaemia | Blood and lymphatic system disorders | 1.3% (1 of 75) | - | 1 |
| Abdominal Discomfort | Gastrointestinal disorders | 1.3% (1 of 75) | - | 1 |
| Abdominal Distension | Gastrointestinal disorders | 1.3% (1 of 75) | - | 1 |
| Abdominal Pain | Gastrointestinal disorders | 1.3% (1 of 75) | - | 1 |
| Abnormal faeces | Gastrointestinal disorders | 1.3% (1 of 75) | - | 1 |
| Dry mouth | Gastrointestinal disorders | 1.3% (1 of 75) | - | 1 |
| Salivary hypersecretion | Gastrointestinal disorders | 1.3% (1 of 75) | - | 1 |
| Administration site reaction | General disorders | 1.3% (1 of 75) | - | 1 |
| Chest discomfort | General disorders | 1.3% (1 of 75) | - | 1 |
| Injection site paraesthesia | General disorders | 1.3% (1 of 75) | - | 1 |
| Injection site warmth | General disorders | 1.3% (1 of 75) | - | 1 |
| Hordeolum | Infections and infestations | 1.3% (1 of 75) | - | 1 |
| Administration related reaction | Injury, poisoning and procedural complications | 1.3% (1 of 75) | - | 1 |
| Alanine aminotransferase increased | Investigations | 1.3% (1 of 75) | - | 1 |
| Blood sodium decreased | Investigations | 1.3% (1 of 75) | - | 1 |
| Myalgia | Musculoskeletal and connective tissue disorders | 1.3% (1 of 75) | - | 1 |
| Pain in jaw | Musculoskeletal and connective tissue disorders | 1.3% (1 of 75) | - | 1 |
Source: ClinicalTrials.gov posted results, read 2026-10-03. A trial lists events above its own reporting threshold, so a rare event may be missing from some trials. Not medical advice.
FDA LABEL
What the FDA label says
Glucagon ANDA208086 · label of 2026-08-11 Regulator
Serious reactions the label warns about: Hypersensitivity and Allergic Reactions.
Gvoke VialDx NDA212097 · label of 2026-07-07 Regulator
Most common adverse reactions (incidence 2% or greater) reported for GVOKE were: Adults - nausea, vomiting, injection site edema raised 1 mm or greater, and headache.
Serious reactions the label warns about: Substantial Increase in Blood Pressure in Patients with Pheochromocytoma, Hypoglycemia in Patients with Insulinoma, Serious Hypersensitivity Reactions, Necrolytic Migratory Erythema, Hyperglycemia with Intravenous Use as a Diagnostic Aid in Patients with Diabetes Mellitus, Hypoglycemia in Patients with Glucagonoma with Intravenous Use as a Diagnostic Aid.
Gvoke HypoPen 0.5 mg Auto-Injector NDA212097 · label of 2025-12-23 Regulator
Most common adverse reactions (incidence 2% or greater) reported for GVOKE were: Adults - nausea, vomiting, injection site edema raised 1 mm or greater, and headache.
Serious reactions the label warns about: Substantial Increase in Blood Pressure in Patients with Pheochromocytoma, Hypoglycemia in Patients with Insulinoma, Serious Hypersensitivity Reactions, Necrolytic Migratory Erythema, Hyperglycemia with Intravenous Use as a Diagnostic Aid in Patients with Diabetes Mellitus, Hypoglycemia in Patients with Glucagonoma with Intravenous Use as a Diagnostic Aid.
REGISTERED STUDIES
1514 registered clinical trials of Glucagon
The 10 most recently updated are listed.
| NCT06861439 | GLP-1s to Enhance Lasting Optimal Weight Status: ACTIVE_NOT_RECRUITING · Updated 2026-10-02 |
|---|---|
| NCT07065552 | Tirzepatide in Obesity-Driven Endometrial Cancer Status: RECRUITING · Updated 2026-10-02 |
| NCT05254314 | Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3) Status: ACTIVE_NOT_RECRUITING · Updated 2026-10-01 |
| NCT07249554 | Combination Therapy for Alcohol Use Disorder Status: NOT_YET_RECRUITING · Updated 2026-10-01 |
| NCT07734792 | Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial Status: NOT_YET_RECRUITING · Updated 2026-10-01 |
| NCT06603571 | A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes Status: COMPLETED · Updated 2026-09-29 |
| NCT07527910 | A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD Status: RECRUITING · Updated 2026-09-29 |
| 2026-525910-77-00 | Using GLP-1 to prevent Post-Transplantation Diabetes Mellitus Status: UNKNOWN · Updated 2026-09-28 |
| NCT06745128 | Tirzepatide for Obesity and Meth Use Disorder Status: COMPLETED · Updated 2026-09-28 |
| NCT07078838 | Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer Status: NOT_YET_RECRUITING · Updated 2026-09-28 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.